Daclizumab
- Generic Name
- Daclizumab
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 38
- Registration Number
- NCT00681343
- Locations
- πΊπΈ
University of Miami Division of Transplantation, Miami, Florida, United States
Phase I/II Thymus Transplantation With Immunosuppression #950
- Conditions
- Interventions
- Biological: Cultured Thymus Tissue for Implantation (CTTI)Other: Cultured Thymus Tissue Implantation and Parental Parathyroid TransplantationProcedure: Blood DrawDrug: Rabbit anti-thymocyte globulinDrug: CyclosporineDrug: TacrolimusDrug: Methylprednisolone or PrednisoloneDrug: DaclizumabDrug: Mycophenolate mofetil
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT00579527
- Locations
- πΊπΈ
Duke University Medical Center, Durham, North Carolina, United States
Fibrosis in Renal Allografts
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- University Hospital, Antwerp
- Target Recruit Count
- 100
- Registration Number
- NCT00493194
- Locations
- π§πͺ
University Hospital Gent, Gent, Oost-Vlaanderen, Belgium
π§πͺUniversity Hospital Brussels, Brussels (Jette), Brabant, Belgium
π§πͺUniversity Hospital Antwerp, Edegem, Antwerp, Belgium
A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 298
- Registration Number
- NCT00363116
- Locations
- πΊπΈ
Cornell University, Ithaca, New York, United States
πΊπΈUniversity of Tennessee, Memphis, Tennessee, United States
πΊπΈUniversity of Wisconsin, Madison, Wisconsin, United States
Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
- Conditions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT00326508
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 198
- Registration Number
- NCT00296348
Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients
- Conditions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT00284531
- Locations
- πΊπΈ
Baylor College of Medicine, Houston, Texas, United States
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 56
- Registration Number
- NCT00275509
- Locations
- πΊπΈ
The Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States
CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- EMagnusson
- Target Recruit Count
- 123
- Registration Number
- NCT00246129
- Locations
- π¬π§
West London Renal and Transplant Centre, 4th Floor Ham House, Hammersmith Hospital, London, United Kingdom
MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Ekberg, Henrik, M.D.
- Target Recruit Count
- 1760
- Registration Number
- NCT00231764
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.